SG11201704829QA - Methods and compositions for treating brain diseases - Google Patents
Methods and compositions for treating brain diseasesInfo
- Publication number
- SG11201704829QA SG11201704829QA SG11201704829QA SG11201704829QA SG11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- brain diseases
- treating brain
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05002—Small monomeric GTPase (3.6.5.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462098085P | 2014-12-30 | 2014-12-30 | |
PCT/US2015/068034 WO2016109649A1 (en) | 2014-12-30 | 2015-12-30 | Methods and compositions for treating brain diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201704829QA true SG11201704829QA (en) | 2017-07-28 |
Family
ID=56285031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201704829QA SG11201704829QA (en) | 2014-12-30 | 2015-12-30 | Methods and compositions for treating brain diseases |
Country Status (12)
Country | Link |
---|---|
US (1) | US11612641B2 (en) |
EP (1) | EP3240577B1 (en) |
JP (1) | JP6782701B2 (en) |
KR (1) | KR102618947B1 (en) |
CN (1) | CN107405414A (en) |
AU (1) | AU2015374043B2 (en) |
BR (1) | BR112017013674A2 (en) |
CA (1) | CA2971687C (en) |
ES (1) | ES2962439T3 (en) |
HK (1) | HK1245127A1 (en) |
SG (1) | SG11201704829QA (en) |
WO (1) | WO2016109649A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114717264A (en) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | Compositions and methods for treating Amyotrophic Lateral Sclerosis (ALS) |
AU2015346164B2 (en) | 2014-11-14 | 2020-01-30 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
ES2962439T3 (en) | 2014-12-30 | 2024-03-19 | Univ Iowa Res Found | Therapeutic agent that activates mTORC1 function for use in the treatment of Huntington's disease |
KR20240056729A (en) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | Modulatory polynucleotides |
KR102427379B1 (en) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | Compositions and methods for treating Huntington's disease |
CL2016003282A1 (en) * | 2016-12-21 | 2017-08-18 | Univ Chile | Aav / igf2 virus, method of genetic treatment and its use in diseases related to protein misfolding such as huntington's disease |
WO2018132791A1 (en) | 2017-01-16 | 2018-07-19 | The Regents Of The University Of California | Treatment of neurodegenerative conditions by disruption of rhes |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050255086A1 (en) * | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US20050009112A1 (en) | 2003-03-07 | 2005-01-13 | Fred Hutchinson Cancer Research Center, Office Of Technology Transfer | Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth |
KR20080018874A (en) | 2005-04-27 | 2008-02-28 | 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. | Materials and methods for enhanced degradation of mutant proteins associated with human disease |
KR101286870B1 (en) * | 2009-11-30 | 2013-07-16 | (주)아모레퍼시픽 | Composition for improving metabolism containing extraction of Astragali Radix |
WO2013061305A1 (en) * | 2011-10-28 | 2013-05-02 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
WO2013067125A1 (en) * | 2011-11-01 | 2013-05-10 | Children's Medical Center Corporation | Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration |
CN106994126A (en) | 2011-11-08 | 2017-08-01 | 因特利凯有限责任公司 | Use the therapeutic scheme of various medicaments |
US9095521B2 (en) * | 2012-02-02 | 2015-08-04 | Washington University | Methods for improving muscle strength |
KR101626526B1 (en) | 2014-10-30 | 2016-06-02 | 경북대학교 산학협력단 | Composition comprising hRheb for preventing or treating Ischemic Brain disease |
ES2962439T3 (en) | 2014-12-30 | 2024-03-19 | Univ Iowa Res Found | Therapeutic agent that activates mTORC1 function for use in the treatment of Huntington's disease |
-
2015
- 2015-12-30 ES ES15876243T patent/ES2962439T3/en active Active
- 2015-12-30 CN CN201580077153.9A patent/CN107405414A/en active Pending
- 2015-12-30 JP JP2017534822A patent/JP6782701B2/en active Active
- 2015-12-30 BR BR112017013674A patent/BR112017013674A2/en not_active Application Discontinuation
- 2015-12-30 WO PCT/US2015/068034 patent/WO2016109649A1/en active Application Filing
- 2015-12-30 CA CA2971687A patent/CA2971687C/en active Active
- 2015-12-30 AU AU2015374043A patent/AU2015374043B2/en active Active
- 2015-12-30 KR KR1020177020915A patent/KR102618947B1/en active IP Right Grant
- 2015-12-30 EP EP15876243.5A patent/EP3240577B1/en active Active
- 2015-12-30 US US15/540,746 patent/US11612641B2/en active Active
- 2015-12-30 SG SG11201704829QA patent/SG11201704829QA/en unknown
-
2018
- 2018-04-11 HK HK18104750.2A patent/HK1245127A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3240577B1 (en) | 2023-07-05 |
WO2016109649A1 (en) | 2016-07-07 |
HK1245127A1 (en) | 2018-08-24 |
JP2018502112A (en) | 2018-01-25 |
CA2971687C (en) | 2024-05-28 |
CN107405414A (en) | 2017-11-28 |
AU2015374043A1 (en) | 2017-07-13 |
JP6782701B2 (en) | 2020-11-11 |
BR112017013674A2 (en) | 2018-02-06 |
AU2015374043B2 (en) | 2021-05-13 |
US20180000907A1 (en) | 2018-01-04 |
CA2971687A1 (en) | 2016-07-07 |
EP3240577A1 (en) | 2017-11-08 |
EP3240577A4 (en) | 2018-07-25 |
ES2962439T3 (en) | 2024-03-19 |
KR102618947B1 (en) | 2023-12-27 |
KR20170098931A (en) | 2017-08-30 |
US11612641B2 (en) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283561B (en) | Methods for treating ocular diseases | |
HK1232141A1 (en) | Methods and compositions for treating huntingtons disease | |
ZA201705673B (en) | Methods for treating skin | |
IL252159A0 (en) | Methods and formulations for treating vascular eye diseases | |
HK1225305A1 (en) | Methods and compositions for treating brain diseases | |
IL246791A0 (en) | Compositions and methods for treating ocular diseases | |
HK1246179A1 (en) | Methods of treating retinal diseases | |
HK1254432A1 (en) | Methods and compositions for treating fibrotic diseases | |
HK1245127A1 (en) | Methods and compositions for treating brain diseases | |
EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
HK1258994A1 (en) | Methods for treatment of diseases | |
ZA201606673B (en) | Compositions and methods for treating neurodegenerative diseases | |
EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
HK1246206A1 (en) | Compositions and methods for treating glaucoma | |
EP3262065C0 (en) | Methods and compositions for treating dystroglycanopathy disorders | |
IL252904A0 (en) | Methods and agents for treating disease | |
HK1244782A1 (en) | Compositions and methods for treating diseases and conditions | |
HK1243937A1 (en) | Methods of treating diseases | |
GB201521083D0 (en) | Compositions for treatment and methods thereof | |
SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes |